Superiority of platelet integrin GPIIb-IIIa receptor antagonist over aspirin in preventing cyclic flow reductions in the guinea pig middle cerebral artery

By Kawano K.-i.   Ikeda Y.   Kondo K.   Umemura K.  

European Journal of Pharmacology, Vol. 374, Iss. 3, 1999-06 ,pp. : 377-385

Elsevier

Access to resources Recommend Favorite

Antithrombotic effect of a humanized anti-GPIIb/IIIa monoclonal antibody, YM207, in a photochemically induced thrombosis model in monkeys

By Kaku S.   Kawasaki T.   Sakai Y.   Taniuchi Y.   Yano S.   Suzuki K.-i.   Terazaki C.   Kawamura K.   Masuho Y.   Satoh N.   Takenaka T.   Yanagi K.   Ohshima N.  

European Journal of Pharmacology, Vol. 279, Iss. 2, 1995-06 ,pp. : 115-121

Elsevier

Access to resources Recommend Favorite

Evaluation of the disintegrin, triflavin, in a rat middle cerebral artery thrombosis model

By Kaku S.   Umemura K.   Mizuno A.   Kawasaki T.   Nakashima M.  

European Journal of Pharmacology, Vol. 321, Iss. 3, 1997-03 ,pp. : 301-305

Elsevier

Access to resources Recommend Favorite

Update on GPIIb/IIIa antagonists

By Hanson Julien   de Leval Xavier   Kolh Philippe   Supuran Claudiu   Pirotte Bernard   Dogné Jean-Michel  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 8, 2003-08 ,pp. : 1173-1188

Informa Healthcare

Access to resources Recommend Favorite

Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in?

By Pen Claude   Lilliu Hervé  

Pharmacy World and Science, Vol. 27, Iss. 2, 2005-04 ,pp. : 83-91

Springer Publishing Company

Access to resources Recommend Favorite